[go: up one dir, main page]

MA46712A - Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire - Google Patents

Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Info

Publication number
MA46712A
MA46712A MA046712A MA46712A MA46712A MA 46712 A MA46712 A MA 46712A MA 046712 A MA046712 A MA 046712A MA 46712 A MA46712 A MA 46712A MA 46712 A MA46712 A MA 46712A
Authority
MA
Morocco
Prior art keywords
combinations
acid chelators
fgfr4 inhibitors
biliary acid
biliary
Prior art date
Application number
MA046712A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Porta Diana Graus
Jacqueline Kinyamu-Akunda
Andreas Joerg Mahl
Luigi Manenti
Andreas Weiss
Armin Wolf
Kuno Wuersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA46712A publication Critical patent/MA46712A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046712A 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire MA46712A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662416222P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
MA46712A true MA46712A (fr) 2019-09-11

Family

ID=60661908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046712A MA46712A (fr) 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Country Status (17)

Country Link
US (1) US11229643B2 (fr)
EP (1) EP3534902B1 (fr)
JP (2) JP7394623B2 (fr)
KR (1) KR102362648B1 (fr)
CN (2) CN117257800A (fr)
AU (1) AU2017354082B2 (fr)
CA (1) CA3042475C (fr)
ES (1) ES2934341T3 (fr)
IL (1) IL266293B (fr)
MA (1) MA46712A (fr)
MX (1) MX387222B (fr)
PL (1) PL3534902T3 (fr)
PT (1) PT3534902T (fr)
RU (1) RU2742033C2 (fr)
SG (1) SG11201903911UA (fr)
WO (1) WO2018083603A1 (fr)
ZA (1) ZA201902744B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054483A1 (fr) 2014-10-03 2016-04-07 Novartis Ag Utilisation de dérivés pyridyle bicycliques à anneaux fusionnés en tant qu'inhibiteurs de fgfr4
CN112759593A (zh) 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569957A (en) 2006-02-10 2012-03-30 Genentech Inc Anti-FGF19 antibodies and methods using same
EP1918376A1 (fr) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
NZ598728A (en) * 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
PL2550972T3 (pl) 2007-04-02 2018-08-31 Genentech, Inc. Przeciwciało agonistyczne Klotho-beta do stosowania w leczeniu cukrzycy lub insulinooporności
US8524212B2 (en) 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US20110212091A1 (en) 2008-09-03 2011-09-01 Licentia Ltd. Materials and methods for inhibiting cancer cell invasion
US20100330175A1 (en) 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
BR112013024717A2 (pt) 2011-04-07 2017-08-08 Genentech Inc anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
US9925242B2 (en) * 2012-12-27 2018-03-27 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
WO2014105849A1 (fr) 2012-12-28 2014-07-03 Xoma (Us) Llc Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation
JP2016520516A (ja) 2013-03-12 2016-07-14 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 線維芽細胞増殖因子４に対するハイブリドーマクローンおよびモノクローナル抗体
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
JP6553589B2 (ja) 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
MY184733A (en) 2013-10-18 2021-04-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
CA2927252C (fr) 2013-10-25 2021-09-28 Novartis Ag Derives pyridyle bicycliques a anneaux fusionnes utilises en tant qu'inhibiteurs de fgfr4
TW201612518A (en) 2014-01-17 2016-04-01 Sanofi Sa Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
WO2015195509A2 (fr) * 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
JP7011939B2 (ja) 2014-08-11 2022-01-27 ダイイチサンキョウヨーロッパ ゲーエムベーハー ヒト抗－ｆｇｆｒ４抗体
WO2016054483A1 (fr) 2014-10-03 2016-04-07 Novartis Ag Utilisation de dérivés pyridyle bicycliques à anneaux fusionnés en tant qu'inhibiteurs de fgfr4
WO2016064960A1 (fr) 2014-10-22 2016-04-28 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (fr) 2015-02-20 2024-02-27 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP2018509448A (ja) * 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
EP3095465A1 (fr) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combinaison d'un inhibiteur de fgfr4 et d'un chélateur d'acides biliaires

Also Published As

Publication number Publication date
KR20190082256A (ko) 2019-07-09
RU2019116061A3 (fr) 2020-12-04
KR102362648B1 (ko) 2022-02-11
AU2017354082B2 (en) 2023-07-27
SG11201903911UA (en) 2019-05-30
ZA201902744B (en) 2021-08-25
RU2742033C2 (ru) 2021-02-01
CA3042475A1 (fr) 2018-05-11
IL266293B (en) 2022-07-01
EP3534902A1 (fr) 2019-09-11
EP3534902B1 (fr) 2022-11-23
JP7394623B2 (ja) 2023-12-08
CA3042475C (fr) 2024-01-16
AU2017354082A1 (en) 2019-05-23
PT3534902T (pt) 2022-12-07
MX387222B (es) 2025-03-18
CN117257800A (zh) 2023-12-22
US20200261444A1 (en) 2020-08-20
CN109922804A (zh) 2019-06-21
ES2934341T3 (es) 2023-02-21
MX2019005194A (es) 2019-08-05
WO2018083603A1 (fr) 2018-05-11
RU2019116061A (ru) 2020-12-04
JP2019533701A (ja) 2019-11-21
JP2022033766A (ja) 2022-03-02
CN109922804B (zh) 2023-11-17
US11229643B2 (en) 2022-01-25
PL3534902T3 (pl) 2023-03-27
IL266293A (en) 2019-06-30
BR112019008787A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
EP3454844A4 (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
PL3761980T3 (pl) Związki aminokwasowe i sposoby zastosowania
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
EP3491149A4 (fr) Traitement d'acide nucléique indépendant
EP3373981A4 (fr) Identification et caractérisation de nouvelles molécules d'inhibiteur de corrosion
EP3630748A4 (fr) Petites molécules inhibitrices d'ire1
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
PL3262183T3 (pl) Test na obecność i wrażliwość bakterii na środki przeciwdrobnoustrojowe
DK3510049T5 (da) Varianter af sur alfa-glucosidase og anvendelser deraf
HRP20211272T8 (hr) 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3390457A4 (fr) Fabrication de nanocellulose et d'intermédiaires de celle-ci en utilisant de d'acide oxalique dihydraté
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3402572A4 (fr) Compositions et méthodes de traitement d'états inflammatoires allergiques
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3113613A4 (fr) Compositions d'ester de choline de l'acide lipoïque et procédés d'utilisation correspondants
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
EP3518995C0 (fr) Composition d'alpha-tcp, de silicate et d'acide aminé phosphorylé